Argos Therapeutics, Inc. Share Price

Stocks

ARGSQ

US0402212023

Pharmaceuticals

OTC Markets Traded
Delayed OTC Markets 5-day change 1st Jan Change
- USD -.--% Intraday chart for Argos Therapeutics, Inc. -6.22% +78.50%

Valuation: Argos Therapeutics, Inc.

Market Cap 3L 3L 3L 2L 4L 3.03Cr 4L 30.14L 11.83L 1.52Cr 11.93L 11.67L 5.05Cr P/E 2016
-2.96x
P/E 2017 -0.22x
Enterprise Value 45.85L 39.69L 37.1L 33.91L 63.9L 44Cr 64.9L 4.35Cr 1.71Cr 22Cr 1.72Cr 1.68Cr 73Cr EV / Sales 2016
200x
EV / Sales 2017 9.19x
Free-Float
88.73%
Yield 2016 *
-
Yield 2017 -
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-6.22% - - 6L
+2.38%+5.24%+46.35%+0.75% 7.83TCr
+0.84%+5.66%-0.15%+27.88% 5.11TCr
+0.90%+1.67%+20.63%+176.54% 4.92TCr
+1.72%+9.27%-48.46%-48.80% 4.47TCr
-0.04%+2.61%+61.78%-23.04% 3.07TCr
+1.63%+2.91%+53.91%+86.05% 2.44TCr
+0.86%+7.93%+133.65%-40.66% 2.36TCr
+2.58%+12.23%+6.63%+202.17% 2.1TCr
-0.62%+3.30%+64.98%+114.68% 1.66TCr
Average +0.98%+2.74%+37.70%+55.06% 3.4TCr
Weighted average by Cap. +1.31%+3.83%+29.62%+42.91%

Financials

2016 2017
Net sales 9L 8L 8L 7L 13.18L 9.02Cr 13.38L 89.71L 35.2L 4.51Cr 35.5L 34.73L 15Cr 18.99L 16.44L 15.37L 14.05L 26.47L 18Cr 26.88L 1.8Cr 70.72L 9.06Cr 71.32L 69.76L 30Cr
Net income -5.3Cr -4.59Cr -4.29Cr -3.92Cr -7.39Cr -505.75Cr -7.51Cr -50Cr -20Cr -253.01Cr -20Cr -19Cr -842.67Cr -4.06Cr -3.51Cr -3.28Cr -3Cr -5.65Cr -387Cr -5.74Cr -39Cr -15Cr -193.61Cr -15Cr -15Cr -644.82Cr
Net Debt -1.31Cr -1.13Cr -1.06Cr -96.94L -1.83Cr -125.02Cr -1.86Cr -12Cr -4.88Cr -63Cr -4.92Cr -4.81Cr -208.31Cr 42.67L 36.94L 34.53L 31.56L 59.47L 41Cr 60.4L 4.05Cr 1.59Cr 20Cr 1.6Cr 1.57Cr 68Cr
Logo Argos Therapeutics, Inc.
Argos Therapeutics, Inc. (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company's Arcelis technology platform utilizes biological components from a patient's own cancer cells or virus to generate individualized immunotherapies. The Company is engaged in the development of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC), and other cancers. It is conducting a pivotal Phase III clinical trial of AGS-003 plus sunitinib or another targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA). It is engaged in the development of AGS-004 for the treatment of Human Immunodeficiency Virus (HIV). It has conducted over three clinical trials of AGS-004, including a Phase IIb clinical trial, Phase IIa clinical trial and Phase I clinical trial.
Employees
-
  1. Stock Market
  2. Stocks
  3. ARGSQ Stock